Protective Effect of Ursodeoxycholic acid in the Chemotherapy Induced Mucositis

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter H.J. Chun
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors H.J. Chun1, S.H. Kim2, J.M. Lee2, I.K. Yoo2, J.M. Lee2, H.S. Choi3, E.S. Kim1, B. Keum2, Y.T. Jeen4, H.S. Lee5, C.D. Kim2
  • 1Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea, /
  • 2Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea, /
  • 3Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Gastrointestinal Medical Instrument Research, Korea University College of Medicine, Seoul, Republic of Korea, /
  • 4Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul, Republic of Korea, /
  • 5Korea University College of Medicine, Seoul, Republic of Korea, /

Abstract

Gastrointestinal mucositis is one of the serious side effect of chemotherapy. It causes dose reduction during chemotherapy and increases the frequency of infection, bleeding risk and length of hospitalization. Ursodeoxycholic acid (UDCA) which is currently being used in a wide variety of liver diseases have also direct cytoprotective effects by stabilizing membranes, inhibiting apoptosis, and acting as an antioxidant. We aimed to assess the protective effect of UDCA in chemotherapy induced mucositis in vivo animal model.